PediaMed Pharmaceuticals, Inc. Acquires Protein Therapeutics; Transaction Focused On Phase II Drug For Autistic Children Who Suffer From Gastrointestinal Dysfunction
10/19/2005 5:10:19 PM
The Pediatrics Company(TM) today announced that it has acquired Protein Therapeutics, a company dedicated to the discovery and development of new therapies for immunological diseases. The acquisition includes an investigational immunoglobulin drug that is entering Phase II clinical trials for gastrointestinal dysfunction in autistic children.
comments powered by